Osify Tablet

Osteoporosis, Osteopenia

Adults: Prevention of Osteoporosis: 500–600 mg elemental calcium daily in divided doses. Treatment of Osteoporosis: 1000–1200 mg elemental calcium daily in divided doses. Supplement with vitamin D (800–1000 IU/day) to optimize calcium metabolism.

Take with meals for better absorption.

Hypercalcemia or hypercalciuria. Severe renal impairment or chronic kidney disease. Known hypersensitivity to bovine-derived products.

Adequate hydration to prevent urinary calcium precipitation. Avoid concurrent use with high-dose calcium supplements. Monitoring Parameters: Serum calcium (to avoid hypercalcemia). Monitor for signs of hypercalcemia (lethargy, arrhythmias). Renal function tests (to prevent nephrotoxicity). Bone mineral density (BMD): Periodically assess therapeutic response.

Not Classi Pregnancy: Not officially classified by FDA; generally considered safe when used as a calcium supplement within recommended limits. Lactation: Likely safe; calcium supplementation helps meet increased maternal demands during breastfeeding.

Reduced absorption with antacids, H2 blockers, and proton pump inhibitors (PPIs). May interact with tetracycline or quinolone antibiotics, reducing their efficacy. Increased risk of hypercalcemia with concurrent vitamin D or thiazide diuretics.

Common: Gastrointestinal discomfort (bloating, nausea, constipation). Rare: Hypercalcemia Nephrolithiasis

Ossein Hydroxyapatite is a bioavailable form of calcium and phosphorus derived from bovine bone. It stimulates bone regeneration by mimicking the natural composition of the bone matrix.

Osify 600 mg Tablet manufactured by General Pharmaceuticals Ltd.. Its generic name is Ossein Hydroxyapatite.